Mutual of America Capital Management LLC Lowers Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Mutual of America Capital Management LLC lowered its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 3.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 41,826 shares of the company’s stock after selling 1,496 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Omnicell were worth $1,574,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Belpointe Asset Management LLC increased its position in shares of Omnicell by 92.2% during the first quarter. Belpointe Asset Management LLC now owns 494 shares of the company’s stock valued at $29,000 after acquiring an additional 237 shares during the last quarter. Covestor Ltd grew its stake in shares of Omnicell by 65.6% in the third quarter. Covestor Ltd now owns 1,355 shares of the company’s stock valued at $61,000 after buying an additional 537 shares in the last quarter. Acadian Asset Management LLC acquired a new position in Omnicell during the 3rd quarter worth about $62,000. Neo Ivy Capital Management purchased a new stake in Omnicell during the third quarter worth about $78,000. Finally, State of Wyoming grew its holdings in shares of Omnicell by 25.7% in the second quarter. State of Wyoming now owns 1,053 shares of the company’s stock valued at $78,000 after purchasing an additional 215 shares in the last quarter. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Benchmark reduced their price objective on Omnicell from $42.00 to $38.00 and set a “buy” rating on the stock in a research note on Friday, February 9th. Barclays assumed coverage on Omnicell in a research report on Wednesday, January 3rd. They set an “underweight” rating and a $33.00 price objective for the company. Finally, Wells Fargo & Company cut their target price on Omnicell from $28.00 to $26.00 and set an “equal weight” rating on the stock in a research report on Friday, February 9th. One analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, Omnicell has an average rating of “Hold” and a consensus price target of $42.20.

Omnicell Stock Performance

Shares of OMCL stock opened at $27.83 on Monday. The stock’s 50-day moving average is $27.73 and its two-hundred day moving average is $32.73. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.22 and a current ratio of 2.52. Omnicell, Inc. has a 1 year low of $25.69 and a 1 year high of $77.14. The firm has a market cap of $1.28 billion, a price-to-earnings ratio of -61.84 and a beta of 0.76.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, February 8th. The company reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.22. The firm had revenue of $258.85 million during the quarter, compared to analysts’ expectations of $256.00 million. Omnicell had a positive return on equity of 3.43% and a negative net margin of 1.78%. Analysts predict that Omnicell, Inc. will post 0.09 earnings per share for the current year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.